📰 Open Label Phase News
Open Label Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Open Label Phase. Real-time updates on events, politics, business and more.
February 13, 2024
Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and...
February 13, 2024
13.02.2024 - Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus ...
February 13, 2024
Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically...
December 22, 2023
AstraZeneca's Wainua receives FDA approval in the US
December 22, 2023
A7568x FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...
November 17, 2023
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent...
November 17, 2023
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...
November 17, 2023
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six.
November 17, 2023
- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...
November 10, 2023
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. ...